| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Inflammation is induced in Br1 cells by spafosic acid trisodium (N-(Phosphonacetacet)-L-aspartate, PALA) therapy [1]. Cells in the accumulation phase can be gradually observed using spafosic acid trisodium (PALA, 300 μM), which also results in a blue cell cycle analysis of cell death [1].
|
|---|---|
| ln Vivo |
In B16 melanoma-bearing mice, trisodium spadronate (490 mg/kg; i.p.; days 1, 5, and 9) resulted in a 77%–86% increase in lifetime above mortality. Trisodium spadronate has been shown to be particularly sensitive to Lewis lung cancer, and subcutaneous injections on days 1, 5, and 9 can cure 50% of Lewis lung cancer ducts [4]. In a mouse infection model, rezafungin (Biafungin) has demonstrated strong in vivo prophylaxis against Pneumocystis jiroveci [1].
|
| Cell Assay |
Cell Cycle Analysis[1]
Cell Types: Br-l established by transplantation of nude mice injected with the human tumor cell line MDA-MB-435 and L-2 cell line. Tested Concentrations: 300 µM. Incubation Duration: 12, 24 and 48 hrs (hours). Experimental Results: Cells in both cell lines were mainly in S phase, but the proportion of S phase cells in L-2 was slightly higher than that in Brl-3prl cells. Western Blot Analysis[1] Cell Types: Br-1 and L-2 cell lines. Tested Concentrations: 300 µM. Incubation Duration: 4, 10 and 24 hrs (hours). Experimental Results: There were moderate differences in the levels of phosphorylated Rb protein in the two cell types. A significant increase in the amount of cyclin A protein was detected in apoptotic L-2 cells, with the highest levels detected 10 hrs (hours) after drug treatment. In contrast, cyclin A levels were not increased in Brl-3prl cells. Cyclin E protein was increased in L-2 cells and Brl-3prl cells compared with respective controls. |
| References |
|
| Molecular Formula |
C6H7NNA3O8P
|
|---|---|
| Molecular Weight |
321.064755678177
|
| Exact Mass |
320.96
|
| CAS # |
70962-66-2
|
| Related CAS # |
Sparfosic acid;51321-79-0
|
| PubChem CID |
154728861
|
| Appearance |
Colorless to off-white solid-liquid Mixture
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
333
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@@H](C(=O)[O-])NC(=O)CP(=O)(O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]
|
| InChi Key |
LKLUEGVLTGGBIX-LHWPGRLPSA-K
|
| InChi Code |
InChI=1S/C6H10NO8P.3Na/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10;;;/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15);;;/q;3*+1/p-3/t3-;;;/m0.../s1
|
| Chemical Name |
trisodium;(2S)-2-[[2-[hydroxy(oxido)phosphoryl]acetyl]amino]butanedioate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~778.67 mM)
DMSO : ~180 mg/mL (~560.64 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.5 mg/mL (14.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.5 mg/mL (14.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 4.5 mg/mL (14.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (311.47 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1147 mL | 15.5734 mL | 31.1468 mL | |
| 5 mM | 0.6229 mL | 3.1147 mL | 6.2294 mL | |
| 10 mM | 0.3115 mL | 1.5573 mL | 3.1147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
